Thermo Fisher Scientific Inc. $TMO is BlueSpruce Investments LP’s 9th Largest Position

BlueSpruce Investments LP boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 665,750 shares of the medical research company’s stock after purchasing an additional 102,704 shares during the period. Thermo Fisher Scientific makes up approximately 6.3% of BlueSpruce Investments LP’s portfolio, making the stock its 9th biggest holding. BlueSpruce Investments LP owned approximately 0.18% of Thermo Fisher Scientific worth $269,935,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in TMO. TIAA Trust National Association lifted its position in shares of Thermo Fisher Scientific by 10.5% during the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock worth $50,256,000 after purchasing an additional 11,817 shares in the last quarter. Lombard Odier Asset Management Switzerland SA lifted its holdings in Thermo Fisher Scientific by 8.4% in the 2nd quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock worth $5,875,000 after buying an additional 1,128 shares in the last quarter. Caledonia Investments PLC boosted its position in Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock valued at $45,299,000 after buying an additional 11,500 shares during the last quarter. Heritage Investors Management Corp increased its position in shares of Thermo Fisher Scientific by 9.6% during the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock worth $22,944,000 after acquiring an additional 4,971 shares during the last quarter. Finally, LBP AM SA lifted its stake in shares of Thermo Fisher Scientific by 13.4% in the second quarter. LBP AM SA now owns 261,038 shares of the medical research company’s stock worth $105,840,000 after acquiring an additional 30,837 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TMO. Leerink Partners raised their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Evercore ISI boosted their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Finally, TD Cowen lifted their target price on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $614.60.

Insider Buying and Selling

In related news, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the sale, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. This trade represents a 36.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Lisa P. Britt sold 1,058 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the transaction, the vice president directly owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 149,271 shares of company stock valued at $86,507,282 in the last quarter. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.2%

TMO stock opened at $572.03 on Friday. The stock has a market cap of $214.92 billion, a PE ratio of 33.05, a price-to-earnings-growth ratio of 4.23 and a beta of 0.90. The firm’s 50-day simple moving average is $565.86 and its 200 day simple moving average is $490.95. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has approved a stock buyback plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.